Collecting blood samples to analyze tumor DNA in patients with high grade gliomas
Circulating Tumor DNA Collection From Patients With High Grade Gliomas
This study is testing a new way to monitor high-grade gliomas by taking blood samples to see how tumor DNA changes in patients before and after their radiation treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05925218 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the monitoring of high-grade gliomas by utilizing a non-surgical approach known as liquid biopsy. It focuses on analyzing circulating tumor DNA (ctDNA) from blood samples of patients diagnosed with high-grade gliomas. The study will enroll 50 patients who will provide up to 10 blood samples over time, allowing researchers to measure changes in ctDNA levels before and after radiotherapy treatment. The goal is to develop a sensitive method for ongoing analysis of tumor biology in these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of high-grade glioma, either prior to surgery or after biopsy.
Not a fit: Patients with a history of another invasive malignancy, except for certain skin cancers, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better monitoring and understanding of high-grade gliomas, potentially improving patient outcomes.
How similar studies have performed: Other studies utilizing liquid biopsy techniques have shown promise in monitoring various cancers, suggesting potential success for this novel approach in high-grade gliomas.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients can be enrolled either prior to a planned surgery/biopsy for a suspected HGG or after biopsy/surgery of pathologically proven, previously untreated HGG, prior to adjuvant radiotherapy * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate * Age ≥18 yrs Exclusion Criteria: * History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years.
Where this trial is running
Toronto, Ontario
- University Health Network — Toronto, Ontario, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.